RxDoctor Payments Data

Deborah Bursey, MD

Endocrinology, Diabetes & Metabolism · Little Rock, ARNPI 1154359099

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $571 of the $733 with a category attached, or 78.0%. 14 manufacturers reported payments, led by Novo Nordisk at 25.9% of the total. 2025 is the largest year on record at $437, 3.4 times the $129 reported in 2019. That places this record below the midpoint for endocrinology, diabetes & metabolism clinicians in AR, where the typical reported total is $5,363.

$733in general payments, 2019–2025

Across 33 payments — averaging $22.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$189
  • Actelion Pharmaceuticals US, Inc.$123
  • Abbott$72
  • Sanofi-aventis U.S. LLC$63
  • Boehringer Ingelheim$53
  • Merck$49
  • plus $184 from 8 others

What the payments were for

  • Food & beverage$57178%
  • Education$16122%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$733 in reported general payments places this provider in the 20th percentile of 43 endocrinology, diabetes & metabolism providers in Arkansas.

See all endocrinology, diabetes & metabolism providers in Arkansas

Medicare billing

Part B allowed, 2024
$47,348
Medicare patients
71
Services billed
526

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide40$43,792
MounjaroTirzepatide25$35,617
TrulicityDulaglutide14$13,694
Tresiba Flextouch U-100Insulin Degludec17$12,667
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog13$5,812
Insulin Lispro Kwikpen U-100Insulin Lispro21$3,969
Humalog Kwikpen U-100Insulin Lispro21$3,426
Lantus SolostarInsulin Glargine,hum.Rec.Anlog33$3,189
Novolog FlexpenInsulin Aspart11$1,413
Ultra-Fine Mini Pen NeedlePen Needle, Diabetic13$835
Levothyroxine Sodium26$211
Metformin Hcl13$65

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$189$43,79240 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 20th percentile of 43 endocrinology, diabetes & metabolism providers in Arkansas.

Other endocrinology, diabetes & metabolism in Little Rock

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →